



Access, Consumption and Use of Antimicrobials

Guest Editors:

Dr. Rabia Hussain

Discipline of Social and
Administrative Pharmacy, School
of Pharmaceutical Sciences,
Universiti Sains Malaysia, Penang
11800, Malaysia

Dr. Jaya Munesarao

Department of Pharmacy,
Penang Hospital, Ministry of
Health Malaysia, George Town,
Penang, Malaysia

Prof. Dr. Zaheer Ud-Din Babar

Department of Pharmacy,
University of Huddersfield,
Huddersfield, UK

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editors

Dear Colleagues,

COVID-19 has affected areas all over the globe, leading to secondary infections. However, there are myriad issues about access, use, and consumption of antimicrobials globally. Few innovative antibiotics are coming to the market, and the treatment options are becoming limited. The emergence of superinfections due to antibiotic misuse and overuse is also posing a serious threat to healthcare systems. In low- and middle-income countries (LMICs), a large number of antibiotics are available without a prescription, contributing to the irrational use of antibiotics. This has led to the development of antibiotic resistance coupled with the emergence of the new and large-scale spread of infections. This is becoming very challenging in terms of our ability to treat the burden of these diseases. This Special Issue will explore the access and utilization of antibiotics in primary and secondary care settings. Papers from all corners of the world are welcome. This includes original research articles, reviews, meta-analyses as well as commentaries.

Dr. Rabia Hussain

Dr. Jaya Munesarao

Prof. Zaheer Ud-Din Babar

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi